Publication: Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT).
No Thumbnail Available
Date
2021-01-01T00:00:00Z
Authors
Authors
Wainberg, Zev A.
Enzinger, Peter C.
Kang, Yoon-Koo
Yamaguchi, Kensei
Qin Shukui, Qin Shukui
Lee, Keun-Wook
Oh, Sang Cheul
Li Jin, Li Jin
TÜRK, HACI MEHMET
Teixeira, Alexandra Carolina
Journal Title
Journal ISSN
Volume Title
Publisher
Metrics
Abstract
Description
Keywords
Citation
Wainberg Z. A. , Enzinger P. C. , Kang Y., Yamaguchi K., Qin Shukui Q. S. , Lee K., Oh S. C. , Li Jin L. J. , TÜRK H. M. , Teixeira A. C. , et al., -Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT).-, JOURNAL OF CLINICAL ONCOLOGY, cilt.39, sa.3, 2021